# A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer

> **NCT00055419** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 744 (actual)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **BIOLOGICAL:** Cetuximab

## Key facts

- **NCT ID:** NCT00055419
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-02
- **Primary completion:** 2004-07
- **Final completion:** 2004-08
- **Target enrollment:** 744 (ACTUAL)
- **Last updated:** 2010-04-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00055419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00055419, "A Study of Cetuximab in Patients Who Have Stage IV Colorectal Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00055419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*